PCSK9 and acute coronary syndrome: Recently, the multicenter, Italian, AT-TARGET-IT registry demonstrated the clinical benefit of a fast-track approach for LLT after an acute coronary syndrome, where a PCSK9 inhibitor was used in all patients.22 Moreover, data from the SWEDEHEART registry showed a lowest risk of cardiovascular events when the on-treatment non-HDL-C goal was early obtained after MI (within 2 months) and maintained thereafter.23 All these findings challenge the stepwise approach for LLT in patients with acute MI,24 which inevitably leads to delay in goal attainment or no goal achievement and possible harm.